China National Biotech Group's Beijing Institute of Biological Products achieves WHO prequalification for polio vaccine again

On July 18th, the 5-dose Sabin strain inactivated polio vaccine independently developed by China National Pharmaceutical Group China National Biotech Group Beijing Institute of Biological Products Research officially received prequalification from the World Health Organization. This is another milestone in the internationalization process of the Beijing Institute of Biological Products Research's polio vaccine, following the prequalification of the 1-dose sIPV in 2022. The approval of this vaccine will effectively reduce transportation and vaccination costs, providing more economical and accessible immunization solutions for developing countries and injecting Chinese strength into the global polio eradication effort.